Reinventing Life Science Startups–Therapeutics and Diagnostics
Steve Blank
AUGUST 19, 2013
has gone offshore primarily due to the toughened regulatory environment. In the last six years half the VC’s in the space have disappeared , unable to raise new funds, and the number of biotech and device startups getting first round financing has dropped by half. Pharma companies are staggering under the costs. Venture Capital Issues.
Let's personalize your content